Welcome to our dedicated page for Constelltn Bnds SEC filings (Ticker: STZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Constellation Brands’ rise from importing Mexican beer to curating a premium wine and craft-spirits portfolio means its SEC disclosures cover everything from hop supply contracts to agave price hedges. If you are searching for “Constellation Brands insider trading Form 4 transactions” or want the annual brewery capacity figures buried in the 10-K, this page brings every document together and explains what it means for cash flow, excise taxes, and brand investments.
Stock Titan’s AI reviews each filing the moment it hits EDGAR, then delivers plain-English takeaways. Use it to navigate a constellation of forms:
- 10-Q quarterly earnings report with depletion-rate trends
- 8-K material events explained—like brewery expansions or wine-asset sales
- Proxy statement executive compensation tied to Modelo sales targets
- Form 4 insider transactions in real-time, highlighting when executives trade after new brand launches
Professionals track three things here: beer segment margins, vineyard divestitures, and cash deployed into Canopy Growth. Stock Titan’s AI-powered summaries spotlight these topics inside each section, so you can finish “Constellation Brands earnings report filing analysis” in minutes rather than hours. Set alerts for “Constellation Brands Form 4 insider transactions real-time,” compare segment revenue across years, or download a “Constellation Brands annual report 10-K simplified” brief before your next client call. Complex disclosures become approachable, letting you decide faster on distribution, hedging, or equity positions.
Biotechnology Value Fund and affiliated entities have filed a Schedule 13G disclosing a collective 7.4% passive stake in Nektar Therapeutics (NASDAQ: NKTR). The filing, dated 9 July 2025 with an event date of 1 July 2025, reports aggregate beneficial ownership of 1,276,595 common shares out of 17,301,061 shares outstanding following the company’s recent public offering.
The ownership is spread across multiple Delaware and Cayman-based vehicles: Biotechnology Value Fund (LP) holds 661,758 shares (3.8%), Biotechnology Value Fund II (LP) holds 517,813 shares (3.0%), and Biotechnology Value Trading Fund OS (LP) holds 71,367 shares (<1%). Control is exercised jointly through the general partners BVF GP Holdings LLC and BVF Partners L.P., with Mark N. Lampert signing on behalf of each entity. All shares are held with shared voting and dispositive power; none of the reporting persons claims sole authority.
The filing is made on Form 13G—indicating a passive investment intent rather than an activist position— and includes the customary certification that the securities were not acquired to influence control of the issuer. No other material transactions, derivatives, or lock-up arrangements are disclosed.
Key take-aways for investors: BVF’s aggregated 7.4% stake makes it one of the largest outside shareholders of Nektar, signalling confidence from a specialist biotech investor group. However, because the filing is passive, immediate governance or strategic changes should not be expected.
WhiteHorse Finance, Inc. (NASDAQ: WHF) has released its 2025 Definitive Proxy Statement. Stockholders as of June 6, 2025 are invited to a fully-virtual annual meeting on July 30, 2025 at 1:00 p.m. ET.
Key voting items
- Proposal 1: Elect two Class I independent directors—G. Stacy Smith and John P. Volpe—for terms expiring in 2028.
- Proposal 2: Ratify Crowe LLP as independent registered public accounting firm for FY 2025.
Ownership & capital
- 23,243,088 shares of common stock outstanding; one vote per share.
- Largest holder: H.I.G. Bayside Loan Opportunity Fund IV, L.P. with 17.1%.
- All officers & directors as a group control 2.5% of shares.
Governance structure
- Seven-member staggered board; four independent directors (majority).
- Independent directors chair Audit, Compensation, and Nominating/Governance committees.
- John Bolduc (H.I.G. Capital) remains non-independent Board Chair; no Lead Independent Director, but Audit Chair Rick P. Puckett acts as liaison.
Advisor & fee highlights
- Base management fee paid to WhiteHorse Advisers totaled $12.1 million for FY 2024; fee rate reduced to 1.75% from 2.00% effective Jan 1 2024.
- Performance-based incentive fee was $9.3 million.
- Administration fees to WhiteHorse Administration were $0.7 million.
Audit & financial controls
- Crowe billed WHF $0.517 million in FY 2024 (audit fees $0.487 million; other fees $0.030 million).
- Audit Committee (all independent) pre-approves all audit/non-audit services; Rick D. Puckett qualified as financial expert.
Director compensation
- Independent director annual retainer increased to $107,500 (from $102,000) effective Oct 30 2024; additional chair fees apply.
Notable governance considerations for investors: management and H.I.G. affiliates continue to hold significant ownership and receive externally-managed fee streams, creating potential conflicts addressed via existing policies. No material business transactions, mergers, or changes in capital structure are proposed.
Everi Holdings Inc. (EVRI) filed a Post-Effective Amendment No. 1 to twelve previously effective Form S-8 registration statements on 1 July 2025. The filing removes from registration all shares of common stock that remain unsold under a range of equity incentive plans dating back to 2006, including the Amended & Restated 2014 Equity Incentive Plan and several legacy Global Cash Access and Multimedia Games plans.
The deregistration is the administrative follow-up to a transformative transaction completed the same day. Under a series of agreements executed on 26 July 2024, Everi and International Game Technology PLC’s (IGT) Gaming & Digital business were simultaneously acquired by Voyager Parent, LLC, an entity owned by funds managed by affiliates of Apollo Global Management. Key closing steps included: (1) IGT transferring its Gaming & Digital assets to a newly formed subsidiary, Spinco; (2) Apollo’s Voyager entities purchasing all Spinco units and the shares of IGT Canada Solutions ULC; and (3) Voyager Merger Sub, Inc. merging with and into Everi, leaving Everi as a wholly owned subsidiary of Apollo-backed Voyager Parent (the “Merger”).
Because Everi will be delisted and its securities deregistered under Section 12(b) of the Exchange Act, the company has terminated all offerings under its outstanding registration statements. Upon effectiveness of this amendment, no additional Everi shares can be issued under the listed employee stock and option plans.
For public investors, the filing signals the formal end of Everi’s status as an SEC-reporting company. For employees and plan participants, any awards not previously settled in connection with the transaction will no longer be serviceable with newly registered shares. No financial results, purchase consideration, or pro-forma figures were disclosed in this document.
FAQ
What is the current stock price of Constelltn Bnds (STZ)?
What is the market cap of Constelltn Bnds (STZ)?
What is the core business of Constellation Brands?
How does Constellation Brands generate its revenue?
What regions does Constellation Brands operate in?
Can you describe the company’s brand portfolio?
How does Constellation Brands address market competition?
What role does strategic investment play in its business model?
How does Constellation Brands maintain operational excellence?
What distinguishes Constellation Brands from its competitors?
